ProMACE－CytaBOM方案与CHOP方案治疗非何杰金淋巴瘤近期疗效比较

Comparison of Short-term Effect of ProMACE-CytaBOM Regimen with CHOP Regimen for Non-Hodgkin' s Lymphoma

报告ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ与ＣＨＯＰ方案治疗ＮＨＬ的结果。将６４例ＮＨＬ随机分为ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ组（治疗组）和ＣＨＯＰ组（对照组）。治疗结果：全组病例中，治疗组总缓解率７８．１％，对照组５９．４％，两组差异无显著性（Ｐ＞０．０５）。在初治病例中，治疗组的缓解率为８９．５％，对照组为５９．１％，两组差异具有显著性（Ｐ＜０．０５）。毒副反应两组均主要表现为白细胞下降、恶心、呕吐、脱发等。无治疗相关死亡发生。作者认为ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案是疗效与安全性较高的方案，可作为治疗中高度恶性ＮＨＬ的首选方案之一。

The results of chemotherapy with ProMACE-CytaBOM and CHOP regimens in non-Hodgkin' s lymphoma(NHL)are reported. Sixty-four cases with NHL were randomized to receive either ProMACE-CytaBOM or CHOP combination chemotherapy.The response rates were 78. 1% for the ProMAE-CytaBOM as compared to 59.4% for the CHOP group,however there was no statistically significant difference between the two groups(P>0.05).In patients treated for the time the response rate was 89.5% and 59.1% respectirely for ProMACE-CytaBOM and CHOP regimen(P<5).The main side-effects included leucopenia,nausea,vomiting and alopecia. No fatal toxicity was encountered.The authors believe that ProMACE-CytaBOM is a safe,effective regimen for patients with intermediate or highgrade NHL.The regimen may be chosen as the first line chemotherapy for NHL.